undamentalytics Newsletter
Sign in

Vistagen Therapeutics, Inc. income statement

In fiscal 2026, Vistagen Therapeutics, Inc. reported revenue of $1.3m, up 161.1% on the year before, operating income of −$72.1m (a -5683.7% margin) and net income of −$69.7m, or −$1.83 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2011Mar 20112012Mar 20122013Mar 20132016Mar 20162017Mar 20172018Mar 20182020Mar 20202021Mar 20212022Mar 20222023Mar 20232024Mar 20242025Mar 20252026Mar 2026LTMJun 2026
Revenue210010011−01013
Research and development4534581312354420395554
General and administrative554146677131514171818
Operating income−7−9−7−18−10−14−21−18−48−59−33−56−72−70
Interest expense3−2−1100————————
Net interest income——————0000————
Income before tax−9−12−13−47−10−14−21−18−48−59−29−51−70−68
Income tax00000000000000
Net income−9−12−13−47−10−14−21−18−48−59−29−51−70−68
Diluted EPS−$0.30−$0.14−$2.00−$145.40−$0.26−$0.19−$0.25−$14.70—−$8.51−$1.52−$1.67−$1.83−$1.66
Diluted shares (average)—147m——2m3m3m3m7m7m19m31m38m41m
EBITDA−7−9−7−18−10−14−21−18−48−59−33−56−72−69

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: KRRO vs VTGNCLGN vs VTGNUPB vs VTGN

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Vistagen Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Vistagen Therapeutics, Inc.